Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The relationship between newly diagnosed acute leukemia (AL) and heart-related lesions remains unclear. This study aimed to investigate baseline cardiac function and risk of cardiovascular diseases (CVDs) in patients with new-onset AL, and provide data on cardiac management strategies for patients with AL. We retrospectively collected data on baseline characteristics, echocardiography, and biochemical blood indicators (e.g., myocardial enzymes) from 408 patients, 200 with newly diagnosed AL, 103 with coronary artery disease (CAD), and 105 controls from January 1, 2015 to August 31, 2019. The creatine kinase isoenzyme myocardial band, lactate dehydrogenase, highly sensitive troponin-I, and B-type natriuretic peptide levels and left ventricular internal diameter (LVID) were significantly higher in patients with newly diagnosed AL than in the control group. The degree of cardiac damage was lower in newly diagnosed AL patients than in CAD patients. The best predictor of heart damage was LVID (AUC [area under the curve] = 0.709; 95% CI [confidence interval]: 0.637-0.781; < 0.001), and independent prognostic risk factors were age and ejection fraction (HR [hazard ratio] = 1.636; 95% CI: 1.039-2.575; = 0.033). The ratio of leukemia blasts among patients with AL was positively correlated with cardiac damage. Our data indicated that newly diagnosed AL patients had certain myocardial damage before treatment. Clinicians need to pay attention to these manifestations, which may be related to the prognosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218202 | PMC |
| http://dx.doi.org/10.3389/fmed.2022.844350 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum heat shock protein family A member 9 protein as a biomarker for bortezomib resistance and poor prognosis in patients with multiple myeloma.
Anticancer Drugs
September 2025
Department of Blood and Marrow Transplantation, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer.
Bortezomib resistance in multiple myeloma (MM) is a significant clinical challenge that limits the long-term effectiveness. Currently, there is a lack of reliable biomarkers to predict bortezomib resistance. Previous studies reported that several proteins regulate bortezomib resistance through targeting ubiquitin-proteasome pathways, including heat shock protein family A member 9 (HSPA9), dickkopf Wnt signaling pathway inhibitor 1 (DKK1), proteasome 26S subunit non-ATPase 14 (PSMD14), and tripartite motif containing 21 (TRIM21).
View Article and Find Full Text PDFDiagnostic symptoms, treatment patterns, and healthcare resource utilization in multiple system atrophy in the United States.
Neurodegener Dis Manag
September 2025
RWE Statistics, KMK Consulting, Inc, North Tower, Morristown, NJ, USA.
Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with diverse symptoms that complicate diagnosis. We aimed to characterize MSA-related symptoms, medications, and healthcare resource utilization (HCRU).
Research Design And Methods: This retrospective cohort study used a large US claims database.
The Predictive Value of Monocyte-to-HDL Cholesterol Ratio in Patients with Dilated Cardiomyopathy and Associated Pulmonary Hypertension.
Cardiovasc Hematol Agents Med Chem
September 2025
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Background: Pulmonary Hypertension (PH) is a significant contributor to cardiac mortality in Dilated Cardiomyopathy (DCM) patients. Inflammatory processes and oxidative stress play pivotal roles in the advancement of Pulmonary Hypertension (PH). The Monocyte-to-High-- Density-Lipoprotein Cholesterol Ratio (MHR), a newly identified biomarker indicative of inflammatory and oxidative stress, has not been extensively researched in the context of pulmonary hypertension, especially within the scope of dilated cardiomyopathy.
View Article and Find Full Text PDFA novel NIR iridium(III) complex-based probe for accurate imaging of mitochondrial biothiols in ferroptosis-mediated lung ischemia-reperfusion injury.
Anal Chim Acta
November 2025
Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266071, China. Electronic address:
Background: Lung ischemia-reperfusion injury (LIRI) is a pathological condition characterized by aggravated oxidative-inflammatory tissue damage that occurs upon blood flow restoration after ischemia. LIRI can lead to severe complications, including primary graft dysfunction in lung transplants and multi-organ failure. However, current treatments remain limited.
View Article and Find Full Text PDFPhase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design.
Contemp Clin Trials
September 2025
Weill Cornell Medicine Center for Global Health, New York, NY, USA.
Introduction: Preclinical and clinical study data show that combining bedaquiline (B or BDQ), moxifloxacin (M), and pyrazinamide (Z), known as BMZ, has potent antimicrobial activity that might shorten treatment duration for drug-susceptible pulmonary tuberculosis.
Methods/design: We describe the design of Tuberculosis Trials Consortium (TBTC) Study 38/CRUSH-TB (NCT05766267), an open-label multicenter international randomized controlled phase 2C trial that compares two four-month regimens, BMZ plus rifabutin (Rb) (2BMZRb/2BMRb) or BMZ plus delamanid (D or DLM) (2BMZD/2BMD), with standard 6-months isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE). All drugs are administered seven days per week, under direct observation, at least five days per week.